Khaled Musallam: No Better Conclusion For a Clinical Trial than For It to Be Published in the LANCET
Khaled Musallam, Director of Thalassemia & Sickle Cell Center at Burjeel Medical City, shared a post on LinkedIn:
“This is how we do it in the UAE!
No better conclusion for a clinical trial than for it to be published in the LANCET (impact factor 98, no.1 Gen Med Journal).
Data from our ENERGIZE phase 3 global RCT showed the efficacy (across all primary and key secondary endpoints) and safety of mitapivat in non-transfusion-dependent thalassemia (NTDT) and is now being used for regulatory filings globally. If approved, mitapivat will be the first oral disease-modifying therapy in beta-NTDT and first ever therapy in alpha-NTDT to be available for patients.
We have been sounding the alarm in the past few years on the harms of un/subtreated anemia (ineffective erythropoiesis/hemolysis) in these patients with significantly increased risks of morbidity and mortality. With this new advance, we hope to transform the prospect of NTDT patients and give them better quality of life.
Big thanks go to all those who believed in this trial, from patients who didn’t hesitate to partake in a placebo-controlled trial, to my research team at BMC | Burjeel Medical City, my sub-investigators at Burjeel Cancer Institute | BCI, and the Department of Health Abu Dhabi for all the support throughout the past two years. Congrats to all my global co-authors, this is BIG.”
More posts related to Hemostasis and more on Hemostasis Today.
-
Jul 11, 2025, 19:14ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
-
Jul 11, 2025, 16:48GPAS 2025: Shaping the Future of Bleeding Disorder Care
-
Jul 10, 2025, 11:23HTRS Thanks CSL Behring for Its Ongoing Commitment to Research Support
-
Jul 9, 2025, 14:11Join Dr. Bethany Samuelson Bannow for a Virtual Event on Hemostasis and Cancer
-
Jul 9, 2025, 13:59Late-Breaking Insights from ISTH 2025: Rurioctocog Alfa Pegol in PUPs with Hemophilia A
-
Jul 12, 2025, 16:21Richard Buka։ Evolution’s Imprint on Blood, Natural Selection Shaping Today’s Hematologic Disorders
-
Jul 12, 2025, 15:337 Tesla MRI Sheds Light on END Mechanisms in Symptomatic MCA Stenosis
-
Jul 12, 2025, 15:221 in 100: Subclavian Steal Syndrome Revealed by LVO Stroke in Case with Persistent Trigeminal Artery
-
Jul 11, 2025, 18:50ICAS Not a Factor: Post-EVT Intensive BP Control within 24 hrs Worsens Outcomes
-
Jul 11, 2025, 17:57Need for Recanalization Strategies Reinforced in P1 and P2: PCA Stroke Poor Outcomes
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 6, 2025, 21:00From Untouchable to Editable: How 21st-Century Gene Editing Breakthroughs Clash with Systemic Barriers
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy
-
Jul 8, 2025, 08:26ASH and HVO Collaborate to Expand Hematology Training in LMICs
-
Jul 6, 2025, 15:02Patients as Experts: EHC Calls for Early Involvement in HTA Systems
-
Jul 6, 2025, 14:56Missed ISTH 2025? Congress Daily Has You Covered
-
Jul 6, 2025, 11:48Japan's Youth Engagement in Hemophilia Care: Where Even the Doctors Get It – HABIT Summit 2025